Cipla
Dr. Ashish Vora, PhD, currently serves as the Lead of Corporate Strategy at Cipla since May 2024. With a strong background in operations and management, previous roles include Manager of Operations at Velsera and Senior Biocurator at PierianDx, where Dr. Vora led a team specializing in cancer biomarker interpretations. Prior experience includes Product Manager at CORE Diagnostics and notable teaching and research roles during an extensive tenure at Old Dominion University, which encompassed award-winning teaching and significant contributions to student funding and organizational budgeting. Dr. Vora began their career as a Research Fellow at Tata Memorial Centre and has held research positions in cancer biology at the University of Leicester. Educational qualifications include a PhD in Biomedical Science from Old Dominion University, an MSc in Cancer, Cell, and Molecular Biology from the University of Leicester, and a BSc (Hons) in Biomedical Science from the University of Central Lancashire.
This person is not in any teams
Cipla
18 followers
Cipla is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.